Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 14/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25939453 | 0.89 | PIK3R2 (0.41) | MCL1DHODHDPP4 | |
| SCHEMBL25939447 | 0.89 | DHODH (0.49) | MCL1DHODHPTPN1DPP4 | |
| SCHEMBL25939422 | 0.81 | MCL1 (0.50) | MCL1DHODHPTPN1KDM5AKDM4C | |
| SCHEMBL15973382 | 0.81 | MCL1 (0.50) | MCL1DHODHPTPN1FTONR1H4 | |
| SCHEMBL25939461 | 0.80 | DHODH (0.58) | DHODH | |
| SCHEMBL15973841 | 0.80 | MCL1 (0.51) | MCL1DHODHPTPN1KDM5AKDM4C | |
| SCHEMBL23645620 | 0.74 | MCL1 (0.63) | MCL1DHODHPTPN1FTONR1H4 | |
| SCHEMBL12362542 | 0.73 | DPP4 (0.46) | DPP4 | |
| SCHEMBL25939425 | 0.73 | DPP4 (0.49) | MCL1DPP4 | |
| SCHEMBL21905208 | 0.72 | DHODH (0.81) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | BRDT, BRPF3, BRD4 | MCL1 52/4885DHODH 441/4885PTPN1 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.